Regueiro-García A, Fariña-Nogueira S, Porto-Arceo J Á, Couselo-Sánchez J M
Pediatric Hematology & Oncology Department, Hospital Clínico Universitario de Santiago, Spain.
Pediatric Hematology & Oncology Department, Hospital Clínico Universitario de Santiago, Spain.
Allergol Immunopathol (Madr). 2018 Jul-Aug;46(4):385-388. doi: 10.1016/j.aller.2017.09.020. Epub 2018 Jan 17.
Chronic granulomatous disease is a primary immunodeficiency caused by mutations in any one of the five components of the NADPH oxidase in phagocytic leucocytes. This causes impaired microbial killing, which leads to severe life-threatening bacterial and fungal infections. Currently, allogenic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for chronic granulomatous disease, although gene therapy may provide a new therapeutic option for the treatment of patients with CGD. Haploidentical HSCT provides a potentially curative treatment option for patients who lack a suitably HLA-matched donor, but only a few cases have been reported in the literature. Herein, we report a boy with X-linked chronic granulomatous disease treated successfully by haploidentical HSCT with post-transplant cyclophosphamide using a treosulfan-based conditioning regimen.
慢性肉芽肿病是一种原发性免疫缺陷病,由吞噬性白细胞中NADPH氧化酶的五个组分中任何一个发生突变引起。这导致微生物杀伤受损,进而引发严重的危及生命的细菌和真菌感染。目前,同种异体造血干细胞移植(HSCT)是慢性肉芽肿病唯一的治愈性治疗方法,尽管基因治疗可能为慢性肉芽肿病患者的治疗提供新的治疗选择。单倍体相合造血干细胞移植为缺乏合适的HLA匹配供体的患者提供了一种潜在的治愈性治疗选择,但文献中仅报道了少数病例。在此,我们报告一名患有X连锁慢性肉芽肿病的男孩,采用基于苏消安的预处理方案,通过单倍体相合造血干细胞移植及移植后环磷酰胺治疗成功。